A Poly(γ, l-glutamic acid)-citric acid based nanoconjugate for cisplatin delivery

Xiong, Yerong; Jiang, Weiwei; Shen, Yan; Li, Huiyi; Sun, Chunmeng; Ouahab, Ammar

doi:10.1016/j.biomaterials.2012.06.071

Cited by 68 publications

(46 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prolonged blood circulation provides the particles with the opportunity to exit the leaky neovasculature and accumulate in tumors. 8 A variety of carriers, including organic (polymeric NPs, 9,10 polymeric micelles, 11,12 polymeric conjugates, 13,14 dendrimers, 15 liposomes, 16,17 polymer-coated liposomes 18 and nanocapsules 19,20 ), inorganic (carbon nanotubes, 21 iron oxide NPs, 22 gold NPs, 22 and mesoporous silica NPs 24 ) and hybrid NPs (nanoscale coordination polymers 25 and polysilsesquioxane NPs 26 ), have been adapted to facilitate delivery of platinum-based drugs (Figure 1). Some of these NP DDSs have demonstrated promising preclinical results, and a few have entered clinical trials (Table 1).…”

Section: Introductionmentioning

confidence: 99%

Nanoparticle formulations of cisplatin for cancer therapy

Duan

Kron

et al. 2016

WIREs Nanomed Nanobiotechnol

144

102

View full text Add to dashboard Cite

The genotoxic agent cisplatin, used alone or in combination with radiation and/or other chemotherapeutic agents, is an important first-line chemotherapy for a broad range of cancers. The clinical utility of cisplatin is limited both by intrinsic and acquired resistance and dose-limiting normal tissue toxicity. That cisplatin shows little selectivity for tumor versus normal tissue may be a critical factor limiting its value. To overcome the low therapeutic ratio of the free drug, macromolecular, liposomal and nanoparticle drug delivery systems have been explored toward leveraging the enhanced permeability and retention (EPR) effect and promoting delivery of cisplatin to tumors. Here, we survey recent advances in nanoparticle formulations of cisplatin, focusing on agents that show promise in preclinical or clinical settings.

show abstract

Section: Introductionmentioning

confidence: 99%

Nanoparticle formulations of cisplatin for cancer therapy

Duan

Kron

et al. 2016

WIREs Nanomed Nanobiotechnol

144

102

View full text Add to dashboard Cite

show abstract

“…Hemolysis studies were carried out for pCD, Taxol, pPTX micelles, pPTX/pCD, AP-1-pPTX micelles and AP-1-pPTX/pCD according to a previous report 45 . The release of haemoglobin from the erythrocytes was used for toxicity measurements of these carriers.…”

Section: Analysis Of Transmittancesmentioning

confidence: 99%

Poly-cyclodextrin and poly-paclitaxel nano-assembly for anticancer therapy

et al. 2014

View full text Add to dashboard Cite

Effective anticancer therapy can be achieved by designing a targeted drug-delivery system with high stability during circulation and efficient uptake by the target tumour cancer cells. We report here a novel nano-assembled drug-delivery system, formed by multivalent host-guest interactions between a polymer-cyclodextrin conjugate and a polymer-paclitaxel conjugate. The multivalent inclusion complexes confer high stability to the nano-assembly, which efficiently delivers paclitaxel into the targeted cancer cells via both passive and active targeting mechanisms. The ester linkages between paclitaxel and the polymer backbone permit efficient release of paclitaxel within the cell by degradation. This novel targeted nano-assembly exhibits significant antitumour activity in a mouse tumour model. The strategy established in this study also provides knowledge for the development of advanced anticancer drug delivery.

show abstract

“…In fact, some cisplatin nano-systems have displayed remarkably prolonged blood circulation and reduced cancer treatment side-effects. [21][22][23][24] For example, Kataoka et al reported polymer-metal complex micelles prepared through the complexation of CDDP with poly(ethylene glycol)-poly( , -aspartic acid) block copolymer in an aqueous medium. 22 Avgoustakis et al reported that the intravenous administration of poly(lactide-co-glycolide)-methoxy-poly(ethylene glycol) (PLGA-mPEG) nanoparticles of CDDP in BALB/c mice resulted in prolonged cisplatin residence in systemic blood circulation.…”

Section: Introductionmentioning

confidence: 98%

Cisplatin Loaded Poly(L-glutamic acid)-g-Methoxy Poly(ethylene glycol) Complex Nanoparticles for Potential Cancer Therapy: Preparation, In Vitro and In Vivo Evaluation

Yu¹,

Tang²,

Li³

et al. 2016

j biomed nanotechnol

View full text Add to dashboard Cite

A series of novel polypeptide-based graft copolymer poly(L-glutamic acid)-graft-methoxy poly(ethylene glycol) (PLG-gmPEG) was synthesized through a Steglich esterification reaction of PLG with mPEG. The structure of the copolymers was confirmed by nuclear magnetic resonance spectra (NMR) and gel permeation chromatography (GPC). MTT assay demonstrated that the PLG-g-mPEGs had good cell compatibility. The unreacted carboxyl groups of the PLG-g-mPEGs were used to complex cisplatin to form polymer-metal complex nanoparticles (CDDP/PLG-g-mPEG) for cancer therapy. The average hydrodynamic radius of the CDDP/PLG-g-mPEG nanoparticles was in the range of 14-25 nm, which was beneficial for solid tumor targeting delivery. A sustained release without initial burst was achieved for the CDDP/PLG-gmPEG nanoparticles, indicating that the CDDP-loaded nanoparticles had great potential to suppress the drug release in blood circulation before the nanoparticles had arrived at targeting tumors. The CDDP/PLG-g-mPEG nanoparticles showed a much longer blood retention profile as compared with the free CDDP. This indicated that the CDDP-loaded nanoparticles had much more opportunity to accumulate in tumor tissue by exerting the EPR effect. In vitro tests demonstrated that the CDDP/PLG-g-mPEG nanoparticles could inhibit the proliferation of HeLa, MCF-7 and A549 cancer cells. At equal dose (4 mg kg −1 ), the CDDP/PLG-g-mPEG nanoparticles showed comparable in vivo antitumor efficacy and significantly lower systemic toxicity as compared with free cis-Diaminedichloroplatinum (cisplatin, CDDP) in MCF-7 tumor bearing mice. These suggested that the CDDP/PLG-g-mPEG nanoparticle drug delivery system had a great potential to be used for cancer therapy.

show abstract

A Poly(γ, l-glutamic acid)-citric acid based nanoconjugate for cisplatin delivery

Cited by 68 publications

References 36 publications

Nanoparticle formulations of cisplatin for cancer therapy

Nanoparticle formulations of cisplatin for cancer therapy

Poly-cyclodextrin and poly-paclitaxel nano-assembly for anticancer therapy

Cisplatin Loaded Poly(L-glutamic acid)-<I>g</I>-Methoxy Poly(ethylene glycol) Complex Nanoparticles for Potential Cancer Therapy: Preparation, <I>In</I> <I>Vitro</I> and <I>In Vivo</I> Evaluation

Contact Info

Product

Resources

About